Chine pharmaceutical company Yabao Pharmaceutical Co. Inc. has partnered with Canadian research facility Lawson Health Research Institute. The new partnership is primarily aimed at improving the lives of healthcare patients and working on more medical studies. 

Yabao made the announcement about the partnership on Tuesday, revealing that it has already engaged in an exclusive license with Lawson in hopes of developing the annexin A5 further for the treatment of sepsis, as per Yahoo! UK & Ireland.

Like Us on Facebook

This week, the joint work on the annexin A5, which was discovered by a Dr. Lim Qingping Feng-led team of scientists, has moved into preclinical development.

"Yabao is pleased to collaborate with Lawson, a leading Canadian research institute focused on improving the lives of patients through medical discovery," Yabao Pharmaceutical Co., President R&D Dr. Peng Wang said.

Dr. Wang went on to say, Yabao is also very pleased that the program has been moving very smoothly, showing great potential as a novel drug candidate for a huge unmet medical need."

"This opportunity for Yabao to further develop leading research into innovative products is further evidence of Yabao's growing commitment to partner the best science to treat serious diseases in China," Dr. Yang finally said.

In response, Lawson Health Research Institute business development manager Kirk Brown said, "Our partnership with Yabao is proving to be very productive for progressing annexin A5 into clinical development and we are highly encouraged by the results to date."

As per the terms of the partnership's agreement, Yabao will have full rights to "discover, develop and commercialize" the annexin A5 in China, Hong Kong and Taiwan. 

The agreement between Yabao and Lawson comes weeks after Yabao's shares resume trade on July 13, as per Reuters.

Meanwhile, Lawson scientists revealed last week that they have discovered a "Jekyll and Hyde" molecule that could slow the development of cancer in early stages.

The said molecule, also called LKB1, can suppress ovarian cancer tumors. 

"We think we might be able to target LKB1 and later metabolism of ovarian cancer to actually kill it. There are no therapeutics against it right now so we have to go back to basics and see how we can do that," said Lawson researcher Dr. Trevor Shepherd on July 22, according to IFPress.com.  

Tagspharmaceutical company, Lawson Health Research Institute